Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
5(100.0%)
5Total
N/A(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06495554Not ApplicableRecruiting

Danish Vulva Cancer Recurrence Study

Role: collaborator

NCT05572801Not ApplicableRecruiting

NOAC9 - Circulating Tumor DNA Guided Follow-Up in Anal Cancer

Role: collaborator

NCT03740126Not ApplicableActive Not Recruiting

Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy

Role: collaborator

NCT04177628Not ApplicableCompleted

Shared Decision Making With Breast Cancer Patients

Role: collaborator

NCT03918382Not ApplicableUnknown

Patient-Reported Outcomes in Head and Neck Cancer

Role: collaborator

All 5 trials loaded